Taysha Gene Therapies (NASDAQ:TSHA) Earns Buy Rating from Chardan Capital

Taysha Gene Therapies (NASDAQ:TSHA)‘s stock had its “buy” rating reaffirmed by Chardan Capital in a note issued to investors on Tuesday,Benzinga reports. They currently have a $12.00 price objective on the stock. Chardan Capital’s target price would suggest a potential upside of 130.55% from the stock’s current price.

A number of other research firms also recently issued reports on TSHA. Wall Street Zen downgraded Taysha Gene Therapies from a “hold” rating to a “sell” rating in a report on Saturday. UBS Group set a $11.00 price target on shares of Taysha Gene Therapies in a research note on Thursday, December 4th. Cantor Fitzgerald restated an “overweight” rating and set a $13.00 price objective on shares of Taysha Gene Therapies in a research note on Friday, November 14th. Needham & Company LLC reaffirmed a “buy” rating and issued a $10.00 target price on shares of Taysha Gene Therapies in a report on Friday, October 17th. Finally, The Goldman Sachs Group set a $11.00 price target on Taysha Gene Therapies in a report on Thursday, December 4th. One investment analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $10.67.

Taysha Gene Therapies Trading Up 6.4%

Shares of NASDAQ:TSHA traded up $0.32 during trading on Tuesday, hitting $5.21. 2,405,941 shares of the company’s stock were exchanged, compared to its average volume of 2,339,102. The company has a current ratio of 10.48, a quick ratio of 10.48 and a debt-to-equity ratio of 0.23. The firm has a market cap of $1.43 billion, a P/E ratio of -15.79 and a beta of 1.02. The firm has a 50-day moving average price of $4.91 and a two-hundred day moving average price of $3.81. Taysha Gene Therapies has a 1-year low of $1.05 and a 1-year high of $6.02.

Taysha Gene Therapies (NASDAQ:TSHA) last posted its earnings results on Tuesday, November 4th. The company reported ($0.09) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.09). Taysha Gene Therapies had a negative return on equity of 67.26% and a negative net margin of 1,144.97%. Equities analysts predict that Taysha Gene Therapies will post -0.35 earnings per share for the current year.

Insider Buying and Selling at Taysha Gene Therapies

In other Taysha Gene Therapies news, insider Sukumar Nagendran sold 260,047 shares of the firm’s stock in a transaction on Monday, December 1st. The stock was sold at an average price of $4.51, for a total transaction of $1,172,811.97. Following the completion of the transaction, the insider owned 1,006,439 shares of the company’s stock, valued at approximately $4,539,039.89. This trade represents a 20.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 3.78% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Taysha Gene Therapies

Several large investors have recently made changes to their positions in the business. Xponance Inc. raised its position in shares of Taysha Gene Therapies by 29.1% in the 3rd quarter. Xponance Inc. now owns 16,575 shares of the company’s stock worth $54,000 after purchasing an additional 3,738 shares during the last quarter. Principal Financial Group Inc. raised its holdings in Taysha Gene Therapies by 33.6% in the third quarter. Principal Financial Group Inc. now owns 16,251 shares of the company’s stock worth $53,000 after buying an additional 4,091 shares during the last quarter. ST Germain D J Co. Inc. raised its holdings in Taysha Gene Therapies by 81.8% in the third quarter. ST Germain D J Co. Inc. now owns 9,633 shares of the company’s stock worth $32,000 after buying an additional 4,333 shares during the last quarter. Legal & General Group Plc lifted its stake in shares of Taysha Gene Therapies by 25.8% in the third quarter. Legal & General Group Plc now owns 23,149 shares of the company’s stock worth $76,000 after buying an additional 4,754 shares in the last quarter. Finally, Quantum Private Wealth LLC grew its holdings in shares of Taysha Gene Therapies by 0.7% during the third quarter. Quantum Private Wealth LLC now owns 822,076 shares of the company’s stock valued at $2,688,000 after buying an additional 6,100 shares during the last quarter. 77.70% of the stock is currently owned by hedge funds and other institutional investors.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.